BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30389030)

  • 1. Histological transformation and secondary malignancies in follicular lymphoma.
    Vitolo U; Chiappella A
    Lancet Haematol; 2018 Nov; 5(11):e496-e497. PubMed ID: 30389030
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group.
    Hirayama Y; Ishitani K; Ota S; Kurosawa M; Kondo T; Takimoto R; Mori A; Sakai H; Torimoto Y; Yamamoto S; Sato K; Iwasaki H; Kohda K; Ishida T; Kakinoki Y; Fukuhara T; Kato J
    Int J Hematol; 2014 Sep; 100(3):281-9. PubMed ID: 25052874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
    Chan TS; Khong PL; Kwong YL
    Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
    Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
    Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
    Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
    Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nodal follicular helper T-cell lymphoma may present with different patterns. A case report.
    Qubaja M; Audouin J; Moulin JC; Molina TJ; Le Tourneau A; Gaulard P; Straub P; Audhuy B; Diebold J
    Hum Pathol; 2009 Feb; 40(2):264-9. PubMed ID: 18760445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent squamous cell carcinoma and follicular lymphoma arising in the scalp after treatment for lymphoma.
    Wada DA; Agarwal N; Florell SR; Lim MS
    Pathology; 2008 Apr; 40(3):316-20. PubMed ID: 18428060
    [No Abstract]   [Full Text] [Related]  

  • 8. New directions in hormone therapy for metastatic breast cancer.
    Namer M
    Ann Oncol; 2002; 13 Suppl 4():69-72. PubMed ID: 12401669
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab for follicular non-Hodgkin lymphoma.
    Gajraj E; Chung H; Longson C; Stevens A
    Lancet Oncol; 2008 Apr; 9(4):320-1. PubMed ID: 18405852
    [No Abstract]   [Full Text] [Related]  

  • 10. The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients.
    Mozas P; Sorigué M; Rivas-Delgado A; Rivero A; Correa JG; Castillo C; Nadeu F; Bataller A; Giné E; Baumann T; Delgado J; Villamor N; Campo E; Magnano L; Sancho JM; López-Guillermo A
    Eur J Haematol; 2021 Mar; 106(3):428-432. PubMed ID: 33247499
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort.
    Rimsza LM; Li H; Braziel RM; Spier CM; Persky DO; Dunlap J; LeBlanc M; Bartlett N; Leonard JP; Smith SM; Press OW; Friedberg JW
    Haematologica; 2018 Apr; 103(4):e151-e153. PubMed ID: 29472351
    [No Abstract]   [Full Text] [Related]  

  • 12. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
    Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
    Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance rituximab should be considered for patients with follicular lymphoma.
    Barr PM
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
    [No Abstract]   [Full Text] [Related]  

  • 14. Secondary central nervous system involvement by follicular lymphoma: case report and review of the literature.
    Grupka NL; Seinfeld J; Ryder J; Lillehei KO; Kleinschmidt-Demasters BK
    Surg Neurol; 2006 Jun; 65(6):590-4. PubMed ID: 16720183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group.
    Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO;
    Leuk Lymphoma; 2003 Nov; 44(11):1903-10. PubMed ID: 14738141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Secondary orbital lymphoma].
    Basanta I; Sevillano C; Álvarez MD
    Arch Soc Esp Oftalmol; 2015 Sep; 90(9):442-4. PubMed ID: 25443214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complete remission with MEC regimen of acute myeloid leukemia (M4) secondary to 5-year treatment of non-Hodgkin lymphoma].
    Satoh Y; Sakuma A; Tuboi I; Hirano H; Yamazaki T; Ashiya M; Kura Y; Irie T; Sawada U; Takeuchi J
    Rinsho Ketsueki; 1992 Nov; 33(11):1730-5. PubMed ID: 1281892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy.
    Guadagnolo BA; Li S; Neuberg D; Ng A; Hua L; Silver B; Stevenson MA; Mauch P
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):928-34. PubMed ID: 16243446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-Hodgkin lymphoma becomes curable].
    Krankenpfl J; 2005; 43(1-3):40-1. PubMed ID: 15912832
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.
    Salles G; Schuster SJ; de Vos S; Wagner-Johnston ND; Viardot A; Blum KA; Flowers CR; Jurczak WJ; Flinn IW; Kahl BS; Martin P; Kim Y; Shreay S; Will M; Sorensen B; Breuleux M; Zinzani PL; Gopal AK
    Haematologica; 2017 Apr; 102(4):e156-e159. PubMed ID: 27979923
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.